TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02950805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a placebo in either period 1 or period 2 by inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive a placebo in either period 1 or period 2 by inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634
Description: Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5634
Description: Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
Study: NCT04086108

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tomato
Description: A maximum of 1 kilo pureed tomatoes, containing 1 gram of GABA.
Study: NCT03247114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Fructose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Fructose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Fructose, 50 grams in 300 ml water at room temperature
Study: NCT04086108

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GABA supplement
Description: 1 gram of GABA dissolved in water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glutamate supplement
Description: A maximum of 8 grams glutamate, adjusted to amount of glutamate given in the tomato arm. Dissolved in water.
Study: NCT03247114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Fructose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Fructose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Fructose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Fructose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Fructose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Fructose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose
Description: Fructose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose, 50 grams in 300 ml water at room temperature
Study: NCT02580279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGCG

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT03247114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Sucrose, 50 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Sucralose, 0.33 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Sucralose, 0.33 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Sucralose, 0.33 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Sucralose, 0.33 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Sucralose, 0.33 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Sucralose, 0.33 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Sucralose, 0.33 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Sucralose, 0.33 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Sucralose, 0.33 grams in 300 ml water at room temperature

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: Sucralose, 0.33 grams in 300 ml water at room temperature
Study: NCT01807520

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Study treatment was provided in pre-filled 1 mL syringes.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Study treatment was provided in pre-filled 1 mL syringes.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was provided in pre-filled 1 mL syringes.
Study: NCT02686255

Intervention type: OTHER
Intervention: complete blood count
Description: complete blood count during follow up in the heart institute
Study: NCT03595748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer mentorship
Description: Participants randomized to this arm of the study will speak with their dialysis peer mentor once a week about fluid intake and adherence to dialysis.
Study: NCT04529980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG (LGG) Probiotic
Description: Lactobacillus rhanmosus GG(LGG®)(Culturelle) is an over the counter dietary supplement that can help to restore the balance in the gut by promoting colonization to support better digestion and immune health.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04947267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Mepivacaine Hydrochloride
Description: 1.8 ml of 3% mepivacaine (3% Scandonest, Septodont) was administered to Group B patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
Study: NCT03348553

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: control group
Description: no supplements given for 16 weeks, after 4 week washout of all supplements and dietetic products

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega2
Description: 2 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products
Study: NCT04947267

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Mepivacaine with 1:100,000 epinephrine
Description: 1.8 ml of 2% mepivacaine with 1:100,000 epinephrine (2% Scandonest Special, Septodont) was administered to Group A patients. Inferior alveolar nerve block was administered to both the groups. Rubber dam was then placed in the desired quadrant. Selected carious mandibular was restored and seven pulpal oxygen saturation spot readings were taken for an hour.
Study: NCT02880176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial Incentive to Increase Ambulation
Description: Financial Incentive and possibility for financial lottery entry in addition to education on the benefits of post-surgery ambulation
Study: NCT02127541

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ga -exendin PET/CT, In- exendin SPECT/CT, MRI
Description: Comparison of different imaging modalities
Study: NCT00576615

Intervention type: DRUG
Intervention: Placebo solution
Description: On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.

Intervention type: DRUG
Intervention: propofol
Description: On the study day you will receive study drug propofol. Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion.~Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
Study: NCT02008370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel infiltration
Description: Exparel infiltrated into wound and chest tube sites
Study: NCT03348553

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega4
Description: 4 capsules of JP+® Omega/d for 16 weeks, after 4 week washout of all supplements and dietetic products

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega2+OGV
Description: 2 capsules of JP+® Omega/d plus 2 capsules each of an encapsulated fruit, vegetable and berry-juice concentrate (6 capsules) for 16 weeks, after 4 week washout of all supplements and dietetic products
Study: NCT00657553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Year 1:1.0 mg/m2. IV. Days 1, 4, 8, 11 every 4 weeks Year 2: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 8 weeks Year 3: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 12 weeks
Study: NCT05402358

Intervention type: OTHER
Intervention: Acceptance and Commitment Therapy Group Intervention
Description: The intervention consists of 7, 2-hour weekly sessions. Session 1 focused on introductions, outlining sessions and sharing experiences. Session 2 introduced key techniques used in the psychological approach (ACT) including mindfulness and understanding difficult thoughts and feelings. Session 3 explored ideas of primary and secondary suffering and reviewed the workability of current coping strategies. Session 4 asked participants to clarify their own personal values. Session 5 focused on goal setting and utilising problem solving skills. Session 6 considered barriers to change including assertiveness communication skills. Session 7 reviewed topics covered over the 6 weeks previously and explored pacing and preparing for setbacks. Finally a follow up 8 weeks later brought participants back for a reunion to review progress with goals and offer an opportunity to address any ongoing issues.

Intervention type: OTHER
Intervention: Acceptance and Commitment Therapy Group Intervention
Description: The intervention consists of 7, 2-hour weekly sessions. Session 1 focused on introductions, outlining sessions and sharing experiences. Session 2 introduced key techniques used in the psychological approach (ACT) including mindfulness and understanding difficult thoughts and feelings. Session 3 explored ideas of primary and secondary suffering and reviewed the workability of current coping strategies. Session 4 asked participants to clarify their own personal values. Session 5 focused on goal setting and utilising problem solving skills. Session 6 considered barriers to change including assertiveness communication skills. Session 7 reviewed topics covered over the 6 weeks previously and explored pacing and preparing for setbacks. Finally a follow up 8 weeks later brought participants back for a reunion to review progress with goals and offer an opportunity to address any ongoing issues.
Study: NCT05802784

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic septoplasty with scissors
Description: In hysteroscopic septoplasty with scissors arm, incision of the septum was done by continuous flow hysteroscopy and scissors using saline as distension media.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hysteroscopic septoplasty with resectoscope
Description: In hysteroscopic septoplasty with resectoscope arm, incision of the septum was done by 26 Fr monopolar resectoscope with collin's knife using glycine1.5% as distension media.
Study: NCT01171989

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK2202083A vaccine
Description: Intramuscular, one dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular, one dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular, one dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Menjugate™
Description: Intramuscular, one dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: NeisVac-C™
Description: Intramuscular, one dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix™
Description: Intramuscular, one dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Synflorix™
Description: Intramuscular, one dose.
Study: NCT01792726

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Boost to the tumour bed
Description: Boost to the tumour bed, with whole breast EBRT delivered according to local policy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Boost to the tumour bed
Description: Boost to the tumour bed, with whole breast EBRT delivered according to local policy.
Study: NCT02104908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: paravertebral nerve
Description: a lumbar, sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: lumbar and sacral plexus block
Description: a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
Study: NCT04528784

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation
Description: Transcutaneous tibial nerve stimulation is a non-invasive electrical stimulation of the posterior tibial nerve, a branch of the sciatic nerve via sacral plexus. In our study the tibial nerve will be stimulated using Transcutaneous Electrical Nerve Stimulation (TENS) unit with two surface adhesive electrodes. The anode will be positioned between 5-10 cm above medial malleolus and posterior to the edge of the tibia and the cathode will be positioned distally on arch of the foot .
Study: NCT02253420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: Part 1 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 12mg Cycle 1 Day 15: Single i.v. dose 12 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 60mg (based on Part 1 data) Cycle 1 Day 15: Single i.v. dose 60mg (based on Part 1 data)~Part 1 \& Part 2~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Cycle 1 Day 12: 2 x 200 mg itraconazole oral (two doses, 12 hours apart) Cycle 1 Days 13-21: 200 mg itraconazole oral, once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: Cycle 1 Days 10 - 21: 600mg Rifampin oral, once daily in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (BAY80-6946)
Description: Cycle 1 Day 1: Single i.v. dose 60mg Cycle 1 Day 15: Single i.v. dose 60mg~Cycle 2 and subsequent cycles:~Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg
Study: NCT04045197

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relaxation Focused Nursing Care
Description: Relaxation Focused Nursing Care is composed of HypnoBirthing and Transactional Model. Hypnobirthing Philosophy is based on the laws of mind and aims to create positive thoughts and emotions. The Transactional Model defines stress as a special relationship between the person and the environment. Therefore, Relaxation Focused Nursing Care; positive language, positive environment and reducing stressors.
Study: NCT02042781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PG545
Description: PG545 will be administered once weekly, as a one hour IV infusion. Patients will be treated until they exhibit disease progression, withdraw due to poor tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 250 mg anticipated.
Study: NCT00601627

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: panitumumab
Study: NCT06789497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lovastatin 60 MG
Description: Participants were given lovastatin 60 mg/day for three consecutive days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were given placebo 60 mg/day for three consecutive days.
Study: NCT03109314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil will be administered to subjects three days before each training, and during training, to evaluate if donepezil improves the effectiveness of training.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: Donepezil will be administered to subjects three days before each training, and during training, to evaluate if donepezil improves the effectiveness of training.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single-letter training
Description: Subjects will undergo training to identify single letters (10,000 trials, or 10 blocks per session for 10 sessions).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Uncrowd training
Description: Subjects will undergo training to identify letters closely flanked by other letters (10,000 trials, or 10 blocks per session for 10 sessions).
Study: NCT00601627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Study: NCT00018044

Intervention type: DRUG
Intervention: Clofazimine
Study: NCT04208724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training
Description: Participate in the training program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cancer Screening intervention
Description: Receive cancer screening intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT04011917

Intervention type: BEHAVIORAL
Intervention: Standard care
Description: Treatment by an extended scope physiotherapist following Standard Operating Procedures.

Intervention type: BEHAVIORAL
Intervention: Standard care
Description: Treatment by an extended scope physiotherapist following Standard Operating Procedures.
Study: NCT00601627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study: NCT03701282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibrutinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT01857167

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil Supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flaxseed Oil Supplementation

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01244022

Intervention type: PROCEDURE
Intervention: colorectal cancer resection
Description: Open radical resection of colorectal cancer, according to oncological principals, depending on the tumor site